About Leuphasyl
Tetrapeptide that mimics enkephalin to modulate facial muscle contraction; competes with enkephalin for opioid receptor sites in neuromuscular junctions; reduces repetitive muscle micro-contractions
Leuphasyl is a synthetic pentapeptide (Tyr-D-Ala-Gly-Phe-Leu-OH) designed as an enkephalin receptor mimic for topical cosmetic applications, formulated as a claimed anti-wrinkle active ingredient based on the theoretical premise that modulation of enkephalin receptor activity at facial neuromuscular junctions could attenuate dynamic muscle contraction and reduce the appearance of expression lines. The proposed mechanism involves enkephalin receptor interaction to attenuate acetylcholine release or signal transmission at the dermal-epidermal neuromuscular interface, conceptually analogous to botulinum toxin in mechanism but operating at significantly lower potency through a distinct receptor pathway; this theoretical framework draws on the established pharmacology of endogenous enkephalins at opioid and related receptors. No clinical trials, controlled in vivo studies, human safety data, or animal efficacy studies for leuphasyl as a distinct compound are indexed in PubMed; the compound appears exclusively in cosmetic ingredient databases and product formulation literature, with no peer-reviewed evidence base in any indexed scientific journal. Leuphasyl has no FDA approval, no drug regulatory status, and no published clinical evidence in any jurisdiction; it is a cosmetic peptide ingredient marketed on a theoretical mechanism, and any claims of efficacy in reducing wrinkles or expression lines are unsupported by independently published clinical or preclinical data.
Leuphasyl Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
Cosmetic peptide (pentapeptide-18), enkephalin analog. Sold as cosmetic anti-wrinkle ingredient. Not regulated as a drug by FDA. No NDA or IND. Cosmetic use only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
1 source cited · 1 moderate
1 Cohort
Integrative In Silico and In Vitro Evaluation of Vialox and Leuphasyl Pentapeptides for Antiaging Applications.
Chem Biodivers · 2026
# Summary Research found that Leuphasyl and Vialox pentapeptides demonstrated distinct mechanisms for potential antiaging applications, with Leuphasyl showing stronger binding to MMP-13 (an enzyme involved in collagen breakdown) and Vialox preferentially targeting SIRT-1 (a cellular longevity regulator). This integrative study combining computational modeling and laboratory testing revealed both peptides exhibited favorable safety profiles and no cytotoxic effects on skin cells, suggesting potential as noninvasive dermocosmetic candidates.
Leuphasyl Side Effects & Safety Considerations
Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Leuphasyl — Providers & Availability
Coverage expanding
No verified providers currently list Leuphasyl. Get notified when one does, or explore providers carrying similar peptides in the Skin & Joint category.
Stay updated on verified Leuphasyl providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Leuphasyl
Leuphasyl is a synthetic pentapeptide (Tyr-D-Ala-Gly-Phe-Leu-OH) designed as an enkephalin receptor mimic for topical cosmetic applications, formulated as a claimed anti-wrinkle active ingredient based on the theoretical premise that modulation of enkephalin receptor activity at facial neuromuscular junctions could attenuate dynamic muscle contraction and reduce the appearance of expression lines. The proposed mechanism involves enkephalin receptor interaction to attenuate acetylcholine release or signal transmission at the dermal-epidermal neuromuscular interface, conceptually analogous to botulinum toxin in mechanism but operating at significantly lower potency through a distinct receptor pathway; this theoretical framework draws on the established pharmacology of endogenous enkephalins at opioid and related receptors.
expression line reduction, facial muscle relaxation, enkephalin pathway modulation.
Research on Leuphasyl primarily documents effects related to expression line reduction and facial muscle relaxation and enkephalin pathway modulation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Leuphasyl include none established for topical use. This is educational information only — consult a qualified healthcare professional before use.
# Summary Research found that Leuphasyl and Vialox pentapeptides demonstrated distinct mechanisms for potential antiaging applications, with Leuphasyl showing stronger binding to MMP-13 (an enzyme involved in collagen breakdown) and Vialox preferentially targeting SIRT-1 (a cellular longevity regulator). This integrative study combining computational modeling and laboratory testing revealed both peptides exhibited favorable safety profiles and no cytotoxic effects on skin cells, suggesting potential as noninvasive dermocosmetic candidates.